Torshamnsgatan 28A Stockholm SE-164 40 Sweden [t] 00 46 8 4777 602
Sidec studies molecular interactions in situ and in vitro using its proprietary technology Protein Tomography.
Sidec offers collaboration research projects to the biopharmaceutical industry and reveals information to prioritise the most promising therapeutic antibody and to locate the antibody binding epitope.
Sidec has together with UCB published the first direct structural evidence of the molecular mechanism of the Synaptic Vesicle protein 2A (SV2A) in mouse brain tissue.
A new version of protein tomography technology has been introduced by Sidec to improve the analysis of therapeutic antibodies and drug targets in biological systems.
